Literature DB >> 8247128

Dopamine D1 receptors facilitate transmitter release.

D L Cameron1, J T Williams.   

Abstract

A physiological role for the dopamine D1 receptor has been difficult to define, particularly because of its complex pre- and postsynaptic localization in brain areas such as the striatum. In the midbrain, however, D1 receptors are selectively localized to the terminals of GABA (gamma-aminobutyric acid)-containing afferents. We have studied the actions of these D1 receptors on evoked GABA synaptic potentials recorded intracellularly from dopamine neurons in the ventral tegmental area (VTA). We report here that dopamine augmented GABAB inhibitory postsynaptic potentials (i.p.s.ps) in the presence of D2 receptor antagonists. This effect was mimicked by the D1 agonists SKF38393 and SKF82958 and blocked by the D1 antagonists SCH23390 and cis-flupenthixol. No modulation of the GABAA synaptic potential was observed. The postsynaptic actions of the GABAB agonist, baclofen, were unaffected by SKF38393, SCH23390 or cis-flupenthixol, confirming a presynaptic locus of D1 action. Additionally, D1 antagonists reduced the amplitude of the GABAB i.p.s.p. in the absence of D1 agonists. We conclude that dopamine acts tonically at presynaptic D1 receptors on the terminals of afferent GABA neurons to facilitate selectively GABAB-mediated neurotransmission in the midbrain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8247128     DOI: 10.1038/366344a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  75 in total

1.  Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine.

Authors:  R Ranaldi; R A Wise
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

2.  Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum.

Authors:  S J Cragg; S A Greenfield
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Dopamine depresses excitatory and inhibitory synaptic transmission by distinct mechanisms in the nucleus accumbens.

Authors:  S M Nicola; R C Malenka
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

4.  Functional connectome of the striatal medium spiny neuron.

Authors:  Nao Chuhma; Kenji F Tanaka; René Hen; Stephen Rayport
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

5.  Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption.

Authors:  Carrie L Walters; Bao-Cheng Wang; Misty Godfrey; Duxin Sun; Colin D Funk; Julie A Blendy
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

Review 6.  Intrinsic and integrative properties of substantia nigra pars reticulata neurons.

Authors:  F-M Zhou; C R Lee
Journal:  Neuroscience       Date:  2011-08-02       Impact factor: 3.590

7.  D1-D2 interaction in feedback control of midbrain dopamine neurons.

Authors:  W X Shi; P L Smith; C L Pun; B Millet; B S Bunney
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

8.  Anatomically dissociable effects of dopamine D1 receptor agonists on reward and relief of withdrawal in morphine-dependent rats.

Authors:  Elena H Chartoff; Matthew F Barhight; Steve D Mague; Allison M Sawyer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

9.  Presynaptic inhibition by dopamine of a discrete component of GABA release in rat substantia nigra pars reticulata.

Authors:  T Miyazaki; M G Lacey
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

10.  Glutamatergic and nonglutamatergic neurons of the ventral tegmental area establish local synaptic contacts with dopaminergic and nondopaminergic neurons.

Authors:  Alice Dobi; Elyssa B Margolis; Hui-Ling Wang; Brandon K Harvey; Marisela Morales
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.